Author Affiliations: Cedars-Sinai Heart Institute, Los Angeles, California (email@example.com).
In Reply: Our Editorial addressed the prevailing confusion in the literature regarding bone marrow–derived cell therapy for heart disease, confusion which was only compounded by the CCTRN's TIME trial.1
First, while the general principle of bone marrow MNC isolation is the same for the manual and automated systems (density gradient-based separation), small details in methods of cell manufacturing can yield cells of different potency.2
Marbán E, Malliaras K. Bone Marrow–Derived Cell Therapy After Myocardial Infarction—Reply. JAMA. 2013;309(14):1459-1460. doi:10.1001/jama.2013.2604